Oxcarbazepine NDC 50742-611

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-611Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0611Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-611-01	50742061101	100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50742-611-01)Marketed from Jun 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxcarbazepine
Generic name (nonproprietary): oxcarbazepine
Active ingredients: Oxcarbazepine — 150 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215796
Marketing start: Jun 1, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 50742-611_69d2a354-3ced-494f-bda2-f3f5c4635eaaSPL ID 69d2a354-3ced-494f-bda2-f3f5c4635eaaSPL set ID 70798ca9-0eda-49c0-8a7c-b775b6ae3d69RxCUI 1365653, 1365842, 1365844UNII VZI5B1W380UPC 0350742611010, 0350742612017, 0350742613014
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742061101 followed by a unit qualifier and the quantity

Package 50742-0611-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 12, 2025.

Indications (excerpt from the label)

Oxcarbazepine extended-release tablets are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. Oxcarbazepine extended-release tablets are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215796

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215796
Product	Strength	Form · route	Labeler	Product NDC
Oxcarbazepine	Oxcarbazepine 300 mg/1	Tablet, Extended releaseOral	Ingenus Pharmaceuticals, LLC	50742-612
Oxcarbazepine	Oxcarbazepine 600 mg/1	Tablet, Extended releaseOral	Ingenus Pharmaceuticals, LLC	50742-613